3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      End-of-life Management of Leadless Cardiac Pacemaker Therapy

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The clinically available leadless pacemakers for patients with a single-chamber pacing indication have shown to be safe and effective. However, the optimal end-of-life strategy of this novel technique is undefined. Suggested strategies comprise of (a) placing an additional leadless device adjacent to the leadless pacemaker, or (b) retrieving the non-functioning leadless pacemaker and subsequently implanting a new device. Although initial studies demonstrate promising results, early experience of acute and mid-term retrieval feasibility and safety remains mixed. We suggest that the approach of leadless pacemaker retrieval is more appealing to limit the amount of non-functioning intracardiac hardware. In addition, potential risks for device–device interference, and unknown long-term complications associated with multiple intracardiac devices are prevented. The potential inability to retrieve chronically implanted leadless pacemakers limits the application of this novel technology. Therefore, long-term prospective analysis is required to define the most optimal end-of-life strategy.

          Related collections

          Author and article information

          Journal
          Arrhythm Electrophysiol Rev
          Arrhythm Electrophysiol Rev
          AER
          Arrhythmia & Electrophysiology Review
          Radcliffe Cardiology
          2050-3369
          2050-3377
          August 2017
          : 6
          : 3
          : 129-133
          Affiliations
          AMC Heart Center, Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
          Author notes

          Disclosure: Dr Beurskens has nothing to declare. Dr Tjong reports consulting fees from Boston Scientific and Abbott. Dr Knops reports consulting fees, research grants and honoraria for Boston Scientific, and consulting fees and research grants with Medtronic and Abbott.

          Correspondence: Dr Niek EG Beurskens, AMC Heart Center, Department of Cardiology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands. E: n.e.beurskens@ 123456amc.nl
          Article
          PMC5614751 PMC5614751 5614751
          10.15420/aer.2017:16:1
          5614751
          29018521
          aef72a24-b602-4296-852a-24ace01a4e59
          Copyright © 2017, Radcliffe Cardiology
          History
          : 14 July 2017
          : 31 July 2017
          Page count
          Pages: 5
          Categories
          Devices

          Leadless pacemaker therapy,end-of-life management,retrieval,Micra Transcatheter Pacing System,Nanostim Leadless Cardiac Pacemaker,transvenous pacemaker

          Comments

          Comment on this article